论文部分内容阅读
目的探讨瑞舒伐他汀对初诊肥胖型2型糖尿病患者炎性反应水平的影响。方法将212例初诊肥胖型2型糖尿病患者随机分为治疗组和对照组各106例。对照组给予盐酸二甲双胍。治疗组在对照组基础上加用瑞舒伐他汀睡前服用。治疗后,对比观察2组治疗前后血清超敏C反应蛋白(hs-CRP)、白细胞介素-1(IL-1)和白细胞介素-6(IL-6)炎性指标的水平。结果治疗前2组hs-CRP、IL-1、IL-6水平差异无统计学意义(P>0.05)。治疗后2组hs-CRP、IL-1、IL-6水平均低于治疗前,且治疗组低于对照组,差异均有统计学意义(P<0.05)。结论瑞舒伐他汀可明显降低初诊肥胖型2型糖尿病患者的炎性反应水平,改善患者的炎症状态,值得进一步开展相关研究探讨其治疗初诊肥胖型2型糖尿病患者的临床意义。
Objective To investigate the effect of rosuvastatin on the inflammatory response in newly diagnosed type 2 diabetic patients with obesity. Methods 212 newly diagnosed obese type 2 diabetic patients were randomly divided into treatment group and control group of 106 cases. The control group was given metformin hydrochloride. The treatment group was given rosuvastatin on the basis of the control group before bedtime. After treatment, the levels of serum hs-CRP, IL-1 and IL-6 in the two groups were compared before and after treatment. Results There was no significant difference in the levels of hs-CRP, IL-1 and IL-6 between the two groups before treatment (P> 0.05). The levels of hs-CRP, IL-1 and IL-6 in the two groups after treatment were lower than those before treatment, and the treatment group was lower than the control group, the difference was statistically significant (P <0.05). Conclusion Rosuvastatin can significantly reduce the level of inflammatory response in newly diagnosed obese type 2 diabetic patients and improve the inflammatory status. It is worth further studying the clinical significance of rosuvastatin in the treatment of newly diagnosed obese type 2 diabetic patients.